1.1834
price down icon1.25%   -0.0166
 
loading
Spero Therapeutics Inc stock is traded at $1.1834, with a volume of 53,039. It is down -1.25% in the last 24 hours and down -7.42% over the past month. Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
See More
Previous Close:
$1.20
Open:
$1.19
24h Volume:
53,039
Relative Volume:
0.23
Market Cap:
$62.16M
Revenue:
$76.19M
Net Income/Loss:
$-1.61M
P/E Ratio:
-4.5515
EPS:
-0.26
Net Cash Flow:
$28.98M
1W Performance:
-5.20%
1M Performance:
-7.42%
6M Performance:
-21.52%
1Y Performance:
-2.07%
1-Day Range:
Value
$1.18
$1.21
1-Week Range:
Value
$1.12
$1.2503
52-Week Range:
Value
$1.01
$1.89

Spero Therapeutics Inc Stock (SPRO) Company Profile

Name
Name
Spero Therapeutics Inc
Name
Phone
857-242-1600
Name
Address
675 MASSACHUSETTS AVENUE, CAMBRIDGE, MA
Name
Employee
46
Name
Twitter
@spero_tx
Name
Next Earnings Date
2024-11-11
Name
Latest SEC Filings
Name
SPRO's Discussions on Twitter

Compare SPRO with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
SPRO 1.185 62.16M 76.19M -1.61M 28.98M -0.26
VRTX 447.30 115.43B 10.63B -479.80M -1.35B 13.33
REGN 745.59 82.04B 13.85B 4.65B 3.32B 35.06
ARGX 592.15 34.86B 1.86B -40.29M -1.28B -4.16
ALNY 249.57 32.09B 2.09B -332.26M 16.06M -4.14
BNTX 104.51 24.49B 3.30B -501.07M 1.03B 11.54

Spero Therapeutics Inc Stock (SPRO) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-23-22 Upgrade Evercore ISI In-line → Outperform
Oct-01-21 Downgrade Oppenheimer Outperform → Perform
Jan-22-21 Reiterated H.C. Wainwright Buy
Dec-16-20 Initiated Berenberg Buy
Sep-29-20 Initiated Evercore ISI Outperform
Nov-05-19 Reiterated H.C. Wainwright Buy
Sep-09-19 Initiated Janney Buy
Feb-09-18 Initiated Cantor Fitzgerald Overweight
Nov-27-17 Initiated BofA/Merrill Neutral
Nov-27-17 Initiated Oppenheimer Outperform
Nov-27-17 Initiated Stifel Buy
View All

Spero Therapeutics Inc Stock (SPRO) Latest News

pulisher
Nov 20, 2024

Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates - MSN

Nov 20, 2024
pulisher
Nov 20, 2024

TD Cowen Reaffirms “Hold” Rating for Spero Therapeutics (NASDAQ:SPRO) - Defense World

Nov 20, 2024
pulisher
Nov 19, 2024

Spero Therapeutics’ (SPRO) “Overweight” Rating Reiterated at Cantor Fitzgerald - Defense World

Nov 19, 2024
pulisher
Nov 18, 2024

Spero Therapeutics (NASDAQ:SPRO) Receives Hold Rating from TD Cowen - MarketBeat

Nov 18, 2024
pulisher
Nov 18, 2024

TD Cowen Downgrades Spero Therapeutics (SPRO) - MSN

Nov 18, 2024
pulisher
Nov 17, 2024

Spero Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance

Nov 17, 2024
pulisher
Nov 16, 2024

Spero Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 16, 2024
pulisher
Nov 15, 2024

Spero Therapeutics (NASDAQ:SPRO) Given "Overweight" Rating at Cantor Fitzgerald - MarketBeat

Nov 15, 2024
pulisher
Nov 15, 2024

Spero Therapeutics earnings beat by $0.18, revenue topped estimates - Investing.com Canada

Nov 15, 2024
pulisher
Nov 14, 2024

Spero Therapeutics Inc. (SPRO) Quarterly 10-Q Report - Quartzy

Nov 14, 2024
pulisher
Nov 14, 2024

Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update - GlobeNewswire

Nov 14, 2024
pulisher
Nov 14, 2024

Spero Therapeutics Reports Wider Q3 Loss, Revenue Falls 47% Amid Restructuring | SPRO Stock News - StockTitan

Nov 14, 2024
pulisher
Nov 13, 2024

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnin - GuruFocus.com

Nov 13, 2024
pulisher
Nov 13, 2024

What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings - Yahoo Finance

Nov 13, 2024
pulisher
Nov 13, 2024

Spero Therapeutics (SPRO) Scheduled to Post Earnings on Thursday - Defense World

Nov 13, 2024
pulisher
Nov 08, 2024

Spero Therapeutics (SPRO) to Release Earnings on Thursday - MarketBeat

Nov 08, 2024
pulisher
Nov 07, 2024

Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 - The Manila Times

Nov 07, 2024
pulisher
Nov 07, 2024

Spero Therapeutics to Report Third Quarter 2024 Financial - GlobeNewswire

Nov 07, 2024
pulisher
Nov 06, 2024

HC Wainwright Expects Higher Earnings for Spero Therapeutics - MarketBeat

Nov 06, 2024
pulisher
Nov 05, 2024

Finance Watch: Syndax Raises $350m, KalVista Gets $100m In Royalty Deals - Citeline News & Insights

Nov 05, 2024
pulisher
Nov 04, 2024

Spero shares hold Buy rating with target lowered on SPR720 Phase 2a results - Investing.com UK

Nov 04, 2024
pulisher
Nov 04, 2024

HC Wainwright Cuts Spero Therapeutics (NASDAQ:SPRO) Price Target to $5.00 - MarketBeat

Nov 04, 2024
pulisher
Nov 02, 2024

There Is A Reason Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Price Is Undemanding - Simply Wall St

Nov 02, 2024
pulisher
Nov 01, 2024

Layoff Tracker: Compass Pathways to Lay Off 30% of Employees - BioSpace

Nov 01, 2024
pulisher
Oct 31, 2024

Cambridge biotech pulls plug on lung disease drug, cuts 39% of workforce - The Business Journals

Oct 31, 2024
pulisher
Oct 31, 2024

Spero Therapeutics to lay off 39% of employees - PharmaLive

Oct 31, 2024
pulisher
Oct 30, 2024

Spero Therapeutics stock hits 52-week low at $1.03 By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Spero Therapeutics to Lay Off 39% of Employees - BioSpace

Oct 30, 2024
pulisher
Oct 30, 2024

Spero Therapeutics stock hits 52-week low at $1.03 - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

Spero’s stock slides after antibiotic flops in Phase II trial - Yahoo Finance

Oct 30, 2024
pulisher
Oct 29, 2024

Spero Therapeutics reports setback in SPR720 study By Investing.com - Investing.com South Africa

Oct 29, 2024
pulisher
Oct 29, 2024

Biopharma Co. Escapes Investor Suit Over Drug Approval Lies - Law360

Oct 29, 2024
pulisher
Oct 29, 2024

Spero Therapeutics Stock Falls 21%, Cuts Jobs, Suspends Pulmonary Treatment Development Program - MarketWatch

Oct 29, 2024
pulisher
Oct 29, 2024

Spero to cut 39% of workforce on failed study, stock plunges 20% (NASDAQ:SPRO) - Seeking Alpha

Oct 29, 2024
pulisher
Oct 29, 2024

Spero Therapeutics reports setback in SPR720 study - Investing.com India

Oct 29, 2024
pulisher
Oct 29, 2024

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update - GlobeNewswire

Oct 29, 2024
pulisher
Oct 29, 2024

Spero Therapeutics Dodges Investor Suit Over FDA Approval (1) - Bloomberg Law

Oct 29, 2024
pulisher
Oct 27, 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap? - Yahoo Finance

Oct 27, 2024
pulisher
Oct 17, 2024

Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 - The Manila Times

Oct 17, 2024
pulisher
Oct 17, 2024

Spero Therapeutics Announces Presentation of SPR719 (Active - GlobeNewswire

Oct 17, 2024
pulisher
Oct 16, 2024

Spero Therapeutics reports promising in vitro NTM treatment data - Investing.com

Oct 16, 2024
pulisher
Oct 15, 2024

Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below Two Hundred Day Moving AverageTime to Sell? - MarketBeat

Oct 15, 2024
pulisher
Oct 09, 2024

Market Insight: Spero Therapeutics Inc (SPRO)’s Notable Drop, Closing at 1.24 - The Dwinnex

Oct 09, 2024
pulisher
Oct 09, 2024

An Analysis of Spero Therapeutics Inc (SPRO)’s Potential Price Growth - Knox Daily

Oct 09, 2024
pulisher
Oct 03, 2024

Spero Therapeutics' (SPRO) "Buy" Rating Reiterated at HC Wainwright - MarketBeat

Oct 03, 2024
pulisher
Oct 02, 2024

Spero Therapeutics reports promising Phase 1 trial results for NTM-PD drug - Investing.com

Oct 02, 2024
pulisher
Oct 02, 2024

Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy - ForexTV.com

Oct 02, 2024
pulisher
Oct 02, 2024

Spero Therapeutics Announces Publication of SPR720 Phase 1 - GlobeNewswire

Oct 02, 2024
pulisher
Sep 24, 2024

Spero Therapeutics (NASDAQ:SPRO) Shares Cross Below 200-Day Moving Average of $1.46 - MarketBeat

Sep 24, 2024
pulisher
Sep 12, 2024

Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Below 200-Day Moving Average of $1.48 - MarketBeat

Sep 12, 2024
pulisher
Sep 11, 2024

Nontuberculous Mycobacterial Infection Market to Exhibit Growth at a CAGR of 13.4% in the US by 2034 | DelveInsight - PR Newswire UK

Sep 11, 2024

Spero Therapeutics Inc Stock (SPRO) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.68
price down icon 0.42%
$18.62
price up icon 0.16%
$36.06
price down icon 1.68%
$364.60
price up icon 0.01%
$196.58
price up icon 0.88%
$102.64
price up icon 0.27%
Cap:     |  Volume (24h):